PoMA

Chanhassen – October 28, 2026 -- Every patient with investigator-assessed clinical deterioration in an exploratory 15-patient glioblastoma analysis showed sustained increases in lactate dehydrogenase (LDH) during treatment, Alpheus Medical, Inc. reported at the ESMO Congress 2026 in Madrid.

Poster 4289P tracks LDH trajectories in 15 recurrent glioblastoma patients

The clinical-stage oncology company presented the data from its first-in-human study of Porphyrin Metabolite Activation (PoMA). The cohort comprised 15 patients with MGMT-unmethylated recurrent glioblastoma. Instead of relying on a single LDH value, the analysis examined how LDH changed over time and how those trajectories related to clinical and radiographic disease status.